These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7921691)

  • 21. Vaccine safety: current systems and recent findings.
    Wharton M
    Curr Opin Pediatr; 2010 Feb; 22(1):88-93. PubMed ID: 19952750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA; David S; Kemmeren JM; Vermeer-de Bondt PE
    Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2732-7. PubMed ID: 18225797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The complicated task of monitoring vaccine safety.
    Ellenberg SS; Chen RT
    Public Health Rep; 1997; 112(1):10-20; discussion 21. PubMed ID: 9018282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N; Nasar A; Suri MF; Qureshi AI
    J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination vaccines: postlicensure safety evaluation.
    Chen RT; Pool V; Takahashi H; Weniger BG; Patel B
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S327-33. PubMed ID: 11709768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse events temporally associated with immunizing agents.
    Duclos P; Pless R; Koch J; Hardy M
    Can Fam Physician; 1993 Sep; 39():1907-13. PubMed ID: 8219839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.
    Gold MS; Gidudu J; Erlewyn-Lajeunesse M; Law B;
    Vaccine; 2010 Jun; 28(28):4487-98. PubMed ID: 20434547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.
    McMahon AW; Iskander J; Haber P; Chang S; Woo EJ; Braun MM; Ball R
    Pediatrics; 2005 Feb; 115(2):453-60. PubMed ID: 15687455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans.
    Moore KM; Duddy A; Braun MM; Platt R; Brown JS
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1137-41. PubMed ID: 18763248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.
    ;
    Expert Rev Vaccines; 2009 Jun; 8(6):705-16. PubMed ID: 19485752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A process for sentinel case review to assess causal relationships between smallpox vaccination and adverse outcomes, 2003-2004.
    Chapman LE; Iskander JK; Chen RT; Neff J; Birkhead GS; Poland G; Gray GC; Siegel J; Sepkowitz K; Robertson RM; Yancy C; Guerra FA; Gardner P; Modlin JF; Maurer T; Berger T; Flanders WD; Shope R
    Clin Infect Dis; 2008 Mar; 46 Suppl 3():S271-93. PubMed ID: 18284368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).
    Sever JL; Brenner AI; Gale AD; Lyle JM; Moulton LH; Ward BJ; West DJ
    Pharmacoepidemiol Drug Saf; 2004 Dec; 13(12):825-40. PubMed ID: 15386719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Essential to monitor vaccine safety].
    Heijbel H
    Lakartidningen; 2001 Sep; 98(36):3777-8. PubMed ID: 11586806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiological approaches to safety investigations.
    Wood JL; Adams VJ
    Vet Microbiol; 2006 Oct; 117(1):66-70. PubMed ID: 16713135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Field evaluation of vaccine safety.
    Tozzi AE
    Vaccine; 2004 May; 22(15-16):2091-5. PubMed ID: 15121330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The monitoring of adverse events following immunization.
    Tatley M
    N Z Med J; 2002 Nov; 115(1165):U247; author reply U247. PubMed ID: 12552289
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs.
    Patel MM; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vaccines and adverse events between risk and fear].
    Meleleo C; Torella I; Fiocco G; Carratta L; Pace L; Zaratti L; Franco E
    Ig Sanita Pubbl; 2010; 66(1):133-8. PubMed ID: 20393615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.